Immuneering (IMRX) Gains from Investment Securities: 2020-2024
Historic Gains from Investment Securities for Immuneering (IMRX) over the last 3 years, with Dec 2024 value amounting to -$5,469.
- Immuneering's Gains from Investment Securities fell 122.68% to -$5,469 in Q4 2024 from the same period last year, while for Dec 2024 it was -$10,057, marking a year-over-year decrease of 10.41%. This contributed to the annual value of -$6,784 for FY2024, which is 72.23% down from last year.
- Per Immuneering's latest filing, its Gains from Investment Securities stood at -$5,469 for Q4 2024, which was down 315.89% from -$1,315 recorded in Q3 2024.
- Over the past 5 years, Immuneering's Gains from Investment Securities peaked at $2.9 million during Q4 2021, and registered a low of -$5,469 during Q4 2024.
- Over the past 3 years, Immuneering's median Gains from Investment Securities value was -$1,886 (recorded in 2023), while the average stood at -$2,649.
- As far as peak fluctuations go, Immuneering's Gains from Investment Securities spiked by 833.83% in 2021, and later slumped by 122.68% in 2024.
- Over the past 5 years, Immuneering's Gains from Investment Securities (Quarterly) stood at $1.8 million in 2020, then surged by 58.75% to $2.9 million in 2021, then crashed by 100.18% to -$5,170 in 2022, then spiked by 52.50% to -$2,456 in 2023, then slumped by 122.68% to -$5,469 in 2024.
- Its Gains from Investment Securities was -$5,469 in Q4 2024, compared to -$1,315 in Q3 2024 and -$2,456 in Q4 2023.